Bugs and irritable bowel syndrome: The good, the bad and the ugly

@article{Ghoshal2010BugsAI,
  title={Bugs and irritable bowel syndrome: The good, the bad and the ugly},
  author={Uday Chand Ghoshal and Hyojin Park and Kok Ann Gwee},
  journal={Journal of Gastroenterology and Hepatology},
  year={2010},
  volume={25}
}
Recently, there has been strong interest in the therapeutic potential of probiotics for irritable bowel syndrome (IBS). At the same time, there is a rapidly growing body of evidence to support an etiological role for gastrointestinal infection and the associated immune activation in the development of post‐infectious IBS. In a more controversial area, small intestinal bacterial overgrowth has been associated with a subset of patients with IBS; the issue of whether it is appropriate to treat a… 
View on Wiley
onlinelibrary.wiley.com
76 Citations
Highly Influential Citations
2
Background Citations
21
Methods Citations
2
Results Citations
1

76 Citations

The role of diet in the pathophysiology and management of irritable bowel syndrome

This hypothesis that diet is a prebiotic for the intestinal microbiota and favors the growth of certain bacteria is supported by the finding that changing to a low-FODMAP diet restores the density of GI cells to the levels in healthy subjects.

The Gut Microbiota and Irritable Bowel Syndrome: Friend or Foe?

The gut microbiota in health, quantitative and qualitative microbiota changes, and therapeutic manipulations targeting the microbiota in patients with IBS are reviewed in this paper.

Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy

A recent proof-of-concept study showing the high frequency of symptom improvement in patients with IBS with SIBO further supports the hypothesis that gut dysbiosis, including small intestinal bacterial overgrowth, causes IBS symptoms.

Irritable bowel syndrome and intestinal parasites: a view from South America.

Routine parasitologicalexamination of stools in individuals who full-fit the criteria for IBS should be included upon initial assessment in endemic countries, with special interest in endemic areas for intestinal parasitism such as South America.

Diet and Irritable Bowel Syndrome, with a Focus on Appetite-Regulating Gut Hormones

Síndrome de intestino irritable y parasitosis intestinal: una visión desde Sud-América

Routine parasitological examination of stools in individuals who full-fit the criteria for IBS should be included upon initial assessment in endemic countries, especially in endemic areas for intestinal parasitism such as South America.

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin

Rifaximin, a nonsystemic antibiotic administered as a 2-week course of therapy, has been shown to be safe and efficacious for the treatment of IBS-D and was not associated with the emergence of bacterial antibiotic resistance.

Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile

The potential mechanism of action of rifaximin, a minimally absorbed antibiotic used to change the gut microbiota, is discussed and the various clinical trials undertaken to study the efficacy and safety profile of the drug are evaluated.

Postinfectious functional gastrointestinal disorders.

  • F. Mearin
  • Medicine
    Journal of clinical gastroenterology
  • 2011
Recent data suggest that anatomic changes to mast cells-nerve fibers are necessary, but not sufficient to induce symptoms, and it is now possible to estimate the risk of developing PI-FGID based on the presence and relative severity of different risk factors.

Is irritable bowel syndrome an organic disorder?

Evidence is presented for the presence of an anatomical defect in IBS patients, namely in the gastrointestinal endocrine cells, which are highly consistent with the other abnormalities reported in Ibs patients, such as visceral hypersensitivity, dysmotility, and abnormal secretion.
...

References

SHOWING 1-10 OF 111 REFERENCES

Almost All Irritable Bowel Syndromes Are Post-Infectious and Respond to Probiotics: Controversial Issues

The discovery that an infective episode may trigger the development of PI-IBS has not substantially changed the clinical management of this subset of patients compared to the classical (non-infective) form of IBS and a number of issues still remain to be elucidated.

Almost all irritable bowel syndromes are post-infectious and respond to probiotics: controversial issues.

The discovery that an infective episode may trigger the development of PI-IBS has not substantially changed the clinical management of this subset of patients compared to the classical (non-infective) form of IBS and a number of issues still remain to be elucidated.

Probiotic Agents in the Treatment of Irritable Bowel Syndrome

  • M. Guslandi
  • Medicine
    The Journal of international medical research
  • 2007
A critical evaluation of the therapeutic role of the various probiotics in IBS is presented and it is shown that minimal inflammatory changes, consistent with the pro-inflammatory role of bacteria, have been demonstrated.

[The effects of probiotics on symptoms of irritable bowel syndrome].

Medilac DS is a safe and useful probiotic agent for the treatment of abdominal pain in patients with IBS and was well tolerated without adverse events.

Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome.

The gastrointestinal and immune effects of SIBO provide a possible unifying framework for understanding frequent observations in IBS, including postprandial bloating and distension, altered motility, visceral hypersensitivity, abnormal brain-gut interaction, autonomic dysfunction, and immune activation.

Bacterial concepts in irritable bowel syndrome.

Once a good clinical response and normalization of the lactulose breath test are achieved, a prokinetic agent may be used to stimulate phase III of interdigestive motility to delay relapse of bacterial overgrowth.

Irritable bowel syndrome in developing countries – a disorder of civilization or colonization?

  • K. Gwee
  • Medicine
    Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2005
It is proposed that loss of this internal protective effect, could give rise to a more uniform worldwide prevalence of IBS.

Is irritable bowel syndrome a low-grade inflammatory bowel disease?

Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome

The results of the study indicate that the administration of Lb.

Postinfectious irritable bowel syndrome.

A small but significant subgroup of patients with irritable bowel syndrome (IBS) report a sudden onset of their IBS symptoms after a bout of gastroenteritis, and some preliminary human data suggest this leads to excessive serotonin release from the mucosa.
...